NEXGEL Announces Strategic Investment in NexGelRx
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy NXGL?
NEXGEL announced that NexGelRx, the Company's previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthcare-commercialization leadership. Gruntfest is a seasoned healthcare executive with over 20 years of experience spanning reimbursement management, payer solutions, and patient support programs. He currently serves as Managing Partner for Diesis Holdings and as CEO of RMBB Health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXGL
About NXGL
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
See More
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.
Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
NEXGEL Secures $1.797 Million Financing for Potential Acquisition
- Financing Amount: NEXGEL announced a financing of $1.797 million for a potential acquisition expected to close in Q1 2026, with funds to be returned to the investor if the transaction does not proceed, indicating the company's proactive approach to mergers and acquisitions.
- Follow-On Investment Potential: The financing may also attract an additional investment of $14.869 million, contingent on the completion of due diligence, which would further enhance the company's acquisition capabilities and market competitiveness.
- CEO Statement: NEXGEL's CEO Adam Levy stated that after successfully integrating several acquisitions in recent years, the company continues to evaluate other accretive transactions, demonstrating its strategic commitment to business expansion.
- Market Positioning: As a leading provider of healthcare and beauty products, NEXGEL's ultra-gentle, high-water-content hydrogel products hold a unique advantage in the market, and future acquisitions will help solidify its market position.
See More
NEXGEL's NexGelRx Secures Investment and Strategic Advisor Appointment
- Strategic Investment: NexGelRx has secured an undisclosed investment from Diesis Holdings, which is expected to enhance its competitive position in the drug delivery sector and drive the development and commercialization of new products.
- Advisor Appointment: Eric Gruntfest has been appointed as a board observer and advisor for NexGelRx, bringing extensive experience in healthcare commercialization and patient access, which will provide new perspectives to the company's strategic development.
- Product Potential: NexGelRx's ultra-gentle hydrogel products are viewed as ideal transdermal delivery mechanisms, anticipated to offer innovative delivery solutions for a wide range of pharmaceuticals, thereby increasing market appeal.
- Market Positioning: With over 20 years of experience in healthcare and consumer products, combined with the new investment and advisor's expertise, NEXGEL is expected to further solidify its leadership position in the health and beauty product market.
See More
Nexgel Revenue Jumps 100% in Fiscal Q2
Financial Performance: Nexgel reported a 100.3% year-over-year increase in GAAP revenue to $2.88 million for Q2 2025, although it fell short of analyst expectations by 6.5%. The company also improved its gross margin significantly to 43.6%, but continued to face net losses and high operating expenses.
Growth Strategy: The company is focusing on expanding its branded product offerings and contract manufacturing partnerships, including a notable collaboration with STADA. Management maintains a full-year revenue target of $13 million and anticipates stronger performance in the second half of the year through new product launches and customer acquisitions.
See More
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
See More
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.
Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
NEXGEL Secures $1.797 Million Financing for Potential Acquisition
- Financing Amount: NEXGEL announced a financing of $1.797 million for a potential acquisition expected to close in Q1 2026, with funds to be returned to the investor if the transaction does not proceed, indicating the company's proactive approach to mergers and acquisitions.
- Follow-On Investment Potential: The financing may also attract an additional investment of $14.869 million, contingent on the completion of due diligence, which would further enhance the company's acquisition capabilities and market competitiveness.
- CEO Statement: NEXGEL's CEO Adam Levy stated that after successfully integrating several acquisitions in recent years, the company continues to evaluate other accretive transactions, demonstrating its strategic commitment to business expansion.
- Market Positioning: As a leading provider of healthcare and beauty products, NEXGEL's ultra-gentle, high-water-content hydrogel products hold a unique advantage in the market, and future acquisitions will help solidify its market position.
See More
NEXGEL's NexGelRx Secures Investment and Strategic Advisor Appointment
- Strategic Investment: NexGelRx has secured an undisclosed investment from Diesis Holdings, which is expected to enhance its competitive position in the drug delivery sector and drive the development and commercialization of new products.
- Advisor Appointment: Eric Gruntfest has been appointed as a board observer and advisor for NexGelRx, bringing extensive experience in healthcare commercialization and patient access, which will provide new perspectives to the company's strategic development.
- Product Potential: NexGelRx's ultra-gentle hydrogel products are viewed as ideal transdermal delivery mechanisms, anticipated to offer innovative delivery solutions for a wide range of pharmaceuticals, thereby increasing market appeal.
- Market Positioning: With over 20 years of experience in healthcare and consumer products, combined with the new investment and advisor's expertise, NEXGEL is expected to further solidify its leadership position in the health and beauty product market.
See More
Nexgel Revenue Jumps 100% in Fiscal Q2
Financial Performance: Nexgel reported a 100.3% year-over-year increase in GAAP revenue to $2.88 million for Q2 2025, although it fell short of analyst expectations by 6.5%. The company also improved its gross margin significantly to 43.6%, but continued to face net losses and high operating expenses.
Growth Strategy: The company is focusing on expanding its branded product offerings and contract manufacturing partnerships, including a notable collaboration with STADA. Management maintains a full-year revenue target of $13 million and anticipates stronger performance in the second half of the year through new product launches and customer acquisitions.
See More
